A novel treatment targeting cancer stem-like cells in esophageal squamous cell carcinoma
Project/Area Number |
18K07959
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 53010:Gastroenterology-related
|
Research Institution | Hokkaido University |
Principal Investigator |
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 癌幹細胞 / 食道扁平上皮癌 / EGFR阻害剤 / MEK阻害剤 / 治療抵抗性 / FGF / CD44 / オーガノイド |
Outline of Final Research Achievements |
The authors have identified CD24Low/CD44High cells as cancer stem-like cells (CSCs) in esophageal squamous cell carcinoma (ESCC). Furthermore, the authors have reported that FGF-2/FGFR/Erk pathway has critical roles in regulating CSCs in ESCC. In the present study, they have shown that FGFR/Erk inhibitors decrease CSCs in ESCC and restore sensitivity to anticancer drugs and radiation in experiments using organoid culture system, organotypic 3D culture system and xenograft experiments. FGFR/Erk inhibitors could be used as a novel therapy targeting CSCs in ESCC.
|
Academic Significance and Societal Importance of the Research Achievements |
多くの癌において分子標的薬が実用化されている中、進行食道扁平上皮癌(ESCC)においては有効な分子標的薬が未だ無いのが現状である。本研究は進行ESCC症例に対する集学的な新規治療法開発の萌芽となる可能性がある。また、本研究で用いた食道扁平上皮癌3次元培養、オーガノイド、動物モデルは生体内に近い形での癌細胞の培養がin vitroで可能であり、通常培養法では困難な癌研究を飛躍的に向上させてきた。これらの研究手法により今後のESCC研究のさらなる向上が期待される。
|
Report
(4 results)
Research Products
(3 results)